Axiom Biosciences, a San Diego-based biotech firm, is taking a contrarian approach by opting for an initial public offering (IPO) in Hong Kong rather than the traditional U.S. market. This decision is driven by the desire to connect with sophisticated biotech investors and clinical partners in Asia, as well as to navigate a tougher fundraising climate in the U.S.
Remo Moomiaie-Qajar, the company's CEO, highlighted that while the U.S. remains a leader in foundational science, Hong Kong's stricter listing standards and recent reforms have made it an appealing venue for biotech firms. The Hang Seng Biotech Index has outperformed U.S. indices, reflecting a growing interest in the sector.
Axiom's strategy also aligns with a broader trend of Chinese biotech firms listing in Hong Kong, as the region's investor base expands and offers lower valuations compared to the Nasdaq. However, local investors often prefer companies with connections to China, which could influence Axiom's success.
The U.S. market is still expected to see a strong wave of biotech IPOs, but Axiom's move underscores the shifting dynamics in global biotech funding, particularly as China enhances its capabilities in drug development. Axiom is also developing a therapy for severe brain injuries in newborns, emphasizing the urgency of advancing clinical trials in Asia.
This strategic pivot may reflect a growing recognition of Hong Kong's potential as a biotech hub, even as the U.S. maintains its status as a deep capital pool for the industry